Item 8.01 Other Events.

On January 13, 2021, UroGen Pharma Ltd. ("UroGen") and The University of Texas MD Anderson Cancer Center ("MD Anderson") announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer.

Under the agreement, MD Anderson and UroGen will collaborate on the design and conduct of pre-clinical and clinical studies with oversight from a joint steering committee. UroGen will provide funding, developmental candidates, and other support.

Item 9.01 Financial Statements and Exhibits.




(d)



Exhibit
Number       Description

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses